{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:17:02Z","timestamp":1789503422050,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI173411-01A1"],"award-info":[{"award-number":["1R01AI173411-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["SEED-Fund"],"award-info":[{"award-number":["SEED-Fund"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01476-y","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:46:10Z","timestamp":1777715170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Superior protection against tuberculosis using heterologous mRNA nanoadjuvant vaccines"],"prefix":"10.1038","volume":"11","author":[{"given":"Bubacarr J. B.","family":"Touray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alieu K.","family":"Faburay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakry F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherein S.","family":"Abdelgayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel M.","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"1476_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240116924 (World Health Organization, 2025)."},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"e036892","DOI":"10.1136\/bmjopen-2020-036892","volume":"10","author":"LF Assebe","year":"2020","unstructured":"Assebe, L. F. et al. Financial burden of HIV and TB among patients in Ethiopia: a cross-sectional survey. BMJ Open 10, e036892 (2020).","journal-title":"BMJ Open"},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470\u2013480 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrd4696","volume":"14","author":"A Zumla","year":"2015","unstructured":"Zumla, A. et al. Towards host-directed therapies for tuberculosis. Nat. Rev. Drug Discov. 14, 511\u2013512 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1476_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijid.2017.01.015","volume":"56","author":"D Valentini","year":"2017","unstructured":"Valentini, D. et al. Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays. Int. J. Infect. Dis. 56, 155\u2013166 (2017).","journal-title":"Int. J. Infect. Dis."},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"a017848","DOI":"10.1101\/cshperspect.a017848","volume":"6","author":"R Loddenkemper","year":"2015","unstructured":"Loddenkemper, R., Lipman, M. & Zumla, A. Clinical aspects of adult tuberculosis. Cold Spring Harb. Perspect. Med. 6, a017848 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698\u2013702 (1994).","journal-title":"JAMA"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.1016\/j.vaccine.2015.08.084","volume":"33","author":"SA Marcus","year":"2015","unstructured":"Marcus, S. A., Steinberg, H. & Talaat, A. M. Protection by novel vaccine candidates, Mycobacterium tuberculosis DeltamosR and DeltaechA7, against challenge with a Mycobacterium tuberculosis Beijing strain. Vaccine 33, 5633\u20135639 (2015).","journal-title":"Vaccine"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","volume":"31","author":"A Arbues","year":"2013","unstructured":"Arbues, A. et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 31, 4867\u20134873 (2013).","journal-title":"Vaccine"},{"key":"1476_CR10","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1016\/j.vaccine.2014.07.047","volume":"32","author":"L Solans","year":"2014","unstructured":"Solans, L. et al. Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. Vaccine 32, 5192\u20135197 (2014).","journal-title":"Vaccine"},{"key":"1476_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00262-8","volume":"6","author":"AD White","year":"2021","unstructured":"White, A. D. et al. MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. NPJ Vaccines 6, 4 (2021).","journal-title":"NPJ Vaccines"},{"key":"1476_CR12","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1016\/j.vaccine.2021.08.018","volume":"39","author":"S Okamura","year":"2021","unstructured":"Okamura, S. & Ebina, H. Could live attenuated vaccines better control COVID-19? Vaccine 39, 5719\u20135726 (2021).","journal-title":"Vaccine"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s10875-019-00642-3","volume":"39","author":"L Poyhonen","year":"2019","unstructured":"Poyhonen, L. et al. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J. Clin. Immunol. 39, 376\u2013390 (2019).","journal-title":"J. Clin. Immunol."},{"key":"1476_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","volume":"133","author":"Medical Advisory Committee of the Immune Deficiency, F.","year":"2014","unstructured":"Medical Advisory Committee of the Immune Deficiency, F. et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J. Allergy Clin. Immunol. 133, 961\u2013966 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1476_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren, O. et al. Phase 2b controlled trial of M72\/AS01(E) vaccine to prevent tuberculosis. N. Engl. J. Med. 379, 1621\u20131634 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1476_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","volume":"199","author":"S Suliman","year":"2019","unstructured":"Suliman, S. et al. Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am. J. Respir. Crit. Care Med. 199, 220\u2013231 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1476_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14\u201320 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"1476_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1476_CR19","doi-asserted-by":"publisher","first-page":"109934","DOI":"10.1016\/j.intimp.2023.109934","volume":"117","author":"MS Mirtaleb","year":"2023","unstructured":"Mirtaleb, M. S. et al. An insight overview on COVID-19 mRNA vaccines: advantageous, pharmacology, mechanism of action, and prospective considerations. Int. Immunopharmacol. 117, 109934 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1476_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics\u2013developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1476_CR21","doi-asserted-by":"publisher","first-page":"1540359","DOI":"10.3389\/fimmu.2025.1540359","volume":"16","author":"CJ De Voss","year":"2025","unstructured":"De Voss, C. J. et al. Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis. Front. Immunol. 16, 1540359 (2025).","journal-title":"Front. Immunol."},{"key":"1476_CR22","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.ebiom.2025.105599","volume":"113","author":"H Lukeman","year":"2025","unstructured":"Lukeman, H. et al. An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4(+) T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis. EBioMedicine 113, 105599 (2025).","journal-title":"EBioMedicine"},{"key":"1476_CR23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1462-5822.2007.00892.x","volume":"9","author":"SC Derrick","year":"2007","unstructured":"Derrick, S. C. & Morris, S. L. The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cell Microbiol. 9, 1547\u20131555 (2007).","journal-title":"Cell Microbiol."},{"key":"1476_CR24","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/S0140-6736(10)60393-5","volume":"375","author":"SH Kaufmann","year":"2010","unstructured":"Kaufmann, S. H., Hussey, G. & Lambert, P. H. New vaccines for tuberculosis. Lancet 375, 2110\u20132119 (2010).","journal-title":"Lancet"},{"key":"1476_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17","author":"C Aagaard","year":"2011","unstructured":"Aagaard, C. et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17, 189\u2013194 (2011).","journal-title":"Nat. Med."},{"key":"1476_CR26","doi-asserted-by":"crossref","unstructured":"Tiwari, S. et al. Infect and inject: how mycobacterium tuberculosis exploits its major virulence-associated type VII SECRETION SYSTEm, ESX-1. Microbiol. Spectr. 7, BAI-0024-2019 (2019).","DOI":"10.1128\/microbiolspec.BAI-0024-2019"},{"key":"1476_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1128\/IAI.68.2.767-778.2000","volume":"68","author":"LY Armitige","year":"2000","unstructured":"Armitige, L. Y. et al. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect. Immun. 68, 767\u2013778 (2000).","journal-title":"Infect. Immun."},{"key":"1476_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1126\/science.1133515","volume":"314","author":"RA Floto","year":"2006","unstructured":"Floto, R. A. et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 314, 454\u2013458 (2006).","journal-title":"Science"},{"key":"1476_CR29","doi-asserted-by":"publisher","first-page":"1188754","DOI":"10.3389\/fimmu.2023.1188754","volume":"14","author":"BJB Touray","year":"2023","unstructured":"Touray, B. J. B. et al. Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis. Front. Immunol. 14, 1188754 (2023).","journal-title":"Front. Immunol."},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.12.031","volume":"172","author":"E Kaufmann","year":"2018","unstructured":"Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176\u2013190.e19 (2018).","journal-title":"Cell"},{"key":"1476_CR31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd4685","volume":"14","author":"JE Zuckerman","year":"2015","unstructured":"Zuckerman, J. E. & Davis, M. E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843\u2013856 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1476_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jps.1023","volume":"90","author":"T Lian","year":"2001","unstructured":"Lian, T. & Ho, R. J. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90, 667\u2013680 (2001).","journal-title":"J. Pharm. Sci."},{"key":"1476_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202001812","volume":"10","author":"W Ho","year":"2021","unstructured":"Ho, W. et al. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv. Health. Mater. 10, e2001812 (2021).","journal-title":"Adv. Health. Mater."},{"key":"1476_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2174\/156652311798192815","volume":"11","author":"C Coban","year":"2011","unstructured":"Coban, C. et al. Novel strategies to improve DNA vaccine immunogenicity. Curr. Gene Ther. 11, 479\u2013484 (2011).","journal-title":"Curr. Gene Ther."},{"key":"1476_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nm859","volume":"9","author":"AS Pym","year":"2003","unstructured":"Pym, A. S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med 9, 533\u2013539 (2003).","journal-title":"Nat. Med"},{"key":"1476_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","volume":"167","author":"LL Lu","year":"2016","unstructured":"Lu, L. L. et al. A functional role for antibodies in tuberculosis. Cell 167, 433\u2013443.e14 (2016).","journal-title":"Cell"},{"key":"1476_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L. et al. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1476_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.coi.2014.06.003","volume":"29","author":"S Sakai","year":"2014","unstructured":"Sakai, S., Mayer-Barber, K. D. & Barber, D. L. Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis. Curr. Opin. Immunol. 29, 137\u2013142 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"1476_CR39","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1016\/j.vaccine.2016.09.002","volume":"34","author":"SG Smith","year":"2016","unstructured":"Smith, S. G. et al. Polyfunctional CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants. Vaccine 34, 5298\u20135305 (2016).","journal-title":"Vaccine"},{"key":"1476_CR40","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/mi.2012.135","volume":"6","author":"R Gopal","year":"2013","unstructured":"Gopal, R. et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 6, 972\u2013984 (2013).","journal-title":"Mucosal Immunol."},{"key":"1476_CR41","doi-asserted-by":"publisher","first-page":"e1004099","DOI":"10.1371\/journal.ppat.1004099","volume":"10","author":"R Gopal","year":"2014","unstructured":"Gopal, R. et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog. 10, e1004099 (2014).","journal-title":"PLoS Pathog."},{"key":"1476_CR42","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/s41590-024-01897-8","volume":"25","author":"M Sun","year":"2024","unstructured":"Sun, M. et al. Specific CD4(+) T cell phenotypes associate with bacterial control in people who \u2018resist\u2019 infection with Mycobacterium tuberculosis. Nat. Immunol. 25, 1411\u20131421 (2024).","journal-title":"Nat. Immunol."},{"key":"1476_CR43","unstructured":"Bancroft, J.D., Stevens, A. & Turner, D.R. Theory and Practice of Histological Techniques.4th Edition, Churchill Livingstone, New York (1996)."},{"key":"1476_CR44","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/nar\/15.3.1281","volume":"15","author":"PM Sharp","year":"1987","unstructured":"Sharp, P. M. & Li, W. H. The codon adaptation Index\u2013a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 15, 1281\u20131295 (1987).","journal-title":"Nucleic Acids Res."},{"key":"1476_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s101260000056","volume":"3","author":"PM Sudha","year":"2001","unstructured":"Sudha, P. M. et al. Multiple tissue transformation in adult zebrafish by gene gun bombardment and muscular injection of naked DNA. Mar. Biotechnol. 3, 119\u2013125 (2001).","journal-title":"Mar. Biotechnol."},{"key":"1476_CR46","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","volume":"27","author":"HX Sun","year":"2009","unstructured":"Sun, H. X., Xie, Y. & Ye, Y. P. Advances in saponin-based adjuvants. Vaccine 27, 1787\u20131796 (2009).","journal-title":"Vaccine"},{"key":"1476_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1586\/erv.11.18","volume":"10","author":"G Ragupathi","year":"2011","unstructured":"Ragupathi, G. et al. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev. Vaccines 10, 463\u2013470 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"1476_CR48","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","volume":"291","author":"R Marty-Roix","year":"2016","unstructured":"Marty-Roix, R. et al. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants. J. Biol. Chem. 291, 1123\u20131136 (2016).","journal-title":"J. Biol. Chem."},{"key":"1476_CR49","doi-asserted-by":"publisher","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","volume":"60","author":"MA Lacaille-Dubois","year":"2019","unstructured":"Lacaille-Dubois, M. A. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review. Phytomedicine 60, 152905 (2019).","journal-title":"Phytomedicine"},{"key":"1476_CR50","doi-asserted-by":"crossref","unstructured":"Chandrasekar, S. S. et al. A novel mucosal adjuvant system for immunization against avian coronavirus causing infectious bronchitis. J. Virol. 94, e01016-20 (2020).","DOI":"10.1128\/JVI.01016-20"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01476-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:03:13Z","timestamp":1783468993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01476-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01476-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}